Technology Forecast: Innovation will be the theme for 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Capsida announces multi-year agreement with Eli Lilly subsidiary
Thousand Oaks-based Capsida Therapeutics has entered into a multi-year agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, to develop transformative genetic medicines for serious diseases, Capisda announced Jan. 4. As per the agreement, Capsida will receive $55 million in the form of an upfront payment and a commitment to participate Read More →
O’Dowd’s fight against Tesla, Musk continues
Elon Musk has been making headlines, mostly at his expense, nearly every day since his $44 billion purchase of Twitter. But for Dan O’Dowd, Musk’s Tesla software is no laughing matter. It has been nearly a year since Dan O’Dowd took out his first full-page newspaper advertisement, highlighting his disdain for Tesla’s assisted-driving technology. But the Read More →
Valeo Networks names new president
Valeo Networks, a spinoff of Camarillo-based Saalex Solutions, announced Eric Ringelberg has been named the new president of the company, replacing Travis Mack, who will now move into a chairman role along with his CEO title. Valeo is headquartered in Rockledge, Florida but has operations in Camarillo. It is a managed security service provider, which Read More →
Atara receives first drug approval
Thousand Oaks-based Atara Biotherapeutics announced on Dec. 19 that the European Commission has approved its drug, Ebvallo. Ebvallo, also known as tabelecleucel, has been Atara’s main product development in its pipeline since 2015. It is the first time Atara has received approval for one of its treatments. The drug is a monotherapy for the treatment Read More →
Amgen buys Horizon Therapeutics for $27B
By Jorge Mercado Senior Staff Writer Thousand Oaks-based Amgen has announced its largest acquisition in company history, $27 billion for Horizon Therapeutics, positioning itself with a pipeline of treatments that could pay dividends over the coming decades. Amgen, one of the largest biotechnology companies in the world, beat out competition from Sanofi and Johnson and Read More →
